Suppr超能文献

评估接受静脉-动脉体外膜肺氧合治疗的新生儿的肝素剂量。

Assessing heparin dosing in neonates on venoarterial extracorporeal membrane oxygenation.

作者信息

Nankervis Craig A, Preston Thomas J, Dysart Kevin C, Wilkinson Whitney D, Chicoine Louis G, Welty Stephen E, Nelin Leif D

机构信息

Neonatal ECMO Program, Columbus Children's Hospital, Columbus, Ohio, USA.

出版信息

ASAIO J. 2007 Jan-Feb;53(1):111-4. doi: 10.1097/01.mat.0000247777.65764.b3.

Abstract

We studied 12 consecutive neonates placed on venoarterial extracorporeal membrane oxygenation (ECMO) in 2004-2005. Activated clotting times (ACT) and anti-factor Xa levels were measured, and the corresponding heparin drip rate was noted. The mean heparin drip rate was 42.2 +/- 10.9 (SD) U/kg/hour (range 20.0-69.5 U/kg/hour). There were 55 simultaneous ACT and anti-factor Xa samples drawn. The mean ACT was 167 +/- 20 seconds (range 128-227 seconds). There was no correlation between ACT levels and heparin dose (r = 0.21; p = 0.12). The mean anti-factor Xa activities were 0.73 +/- 0.19 U/ml (range 0.1-1.0 U/ml). There was a correlation (r = 0.75; p < 0.0001) between anti-factor Xa and heparin dose. We also examined the effect of day on ECMO on heparin drip rate, ACT, and anti-factor Xa. There was no correlation between day on ECMO and either heparin drip rate (r = 0.21, p = 0.12) or ACT (r = 0.002, p = 0.99). However, there was a positive correlation (r = 0.46, p < 0.0005) between day on ECMO and anti-factor Xa activities. In these neonatal patients on venoarterial ECMO, ACT was not a reliable indicator of heparin effect. Furthermore, the increase in anti-factor Xa levels with time on ECMO suggests that heparin accumulates and/or that anti-thrombin III levels decrease with time on ECMO.

摘要

我们研究了2004年至2005年期间连续接受静脉-动脉体外膜肺氧合(ECMO)治疗的12例新生儿。测量活化凝血时间(ACT)和抗Xa因子水平,并记录相应的肝素滴注速率。肝素平均滴注速率为42.2±10.9(标准差)U/kg/小时(范围为20.0 - 69.5 U/kg/小时)。共采集了55份ACT和抗Xa因子的同步样本。ACT平均为167±20秒(范围为128 - 227秒)。ACT水平与肝素剂量之间无相关性(r = 0.21;p = 0.12)。抗Xa因子平均活性为0.73±0.19 U/ml(范围为0.1 - 1.0 U/ml)。抗Xa因子与肝素剂量之间存在相关性(r = 0.75;p < 0.0001)。我们还研究了ECMO治疗天数对肝素滴注速率、ACT和抗Xa因子的影响。ECMO治疗天数与肝素滴注速率(r = 0.21,p = 0.12)或ACT(r = 0.002,p = 0.99)均无相关性。然而,ECMO治疗天数与抗Xa因子活性之间存在正相关性(r = 0.46,p < 0.0005)。在这些接受静脉-动脉ECMO治疗的新生儿患者中,ACT并非肝素效果的可靠指标。此外,随着ECMO治疗时间的延长,抗Xa因子水平升高表明肝素会蓄积和/或抗凝血酶III水平会随着ECMO治疗时间的延长而降低。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验